Double-blind study to evaluate efficacy and safety of meloxicam 7.5 mg and 15 mg versus mefenamic acid 1500 mg in the treatment of primary dysmenorrhea

Acta Obstetricia et Gynecologica Scandinavica

Volumn 83, Issue 7, 2004, Pages 667-673

  De Mello, Nilson Roberto ^a   Baracat, Edmund Chada ^a   Tomaz, Geraldez ^a   Bedone, Aloísio José ^a   Camargos, Aroldo ^a   Barbosa, Ione Cristina ^a   De Souza, Rosival Nassar ^a   Rumi, Demetrio Ortega ^a,b   Martinez Alcala, Felix Octavio ^a   Aldrete Velasco, Jorge Antonio ^a   Risco Cortes, Roberto Jose ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Lumbar pain; Mefenamic acid; Meloxicam; Primary dysmenorrhea

Indexed keywords

AMINOTRANSFERASE; HEMOGLOBIN; MEFENAMIC ACID; MELOXICAM;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENTAL CARIES; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSMENORRHEA; DYSPNEA; FEMALE; FISHER EXACT TEST; GASTRITIS; GASTROINTESTINAL DISEASE; HEMATOCRIT; HUMAN; IRRITABLE COLON; KRUSKAL WALLIS TEST; LABORATORY TEST; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MULTICENTER STUDY; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH DISTENSION; VOMITING; WILCOXON SIGNED RANKS TEST;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; DYSMENORRHEA; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MEFENAMIC ACID; THIAZINES; THIAZOLES; TREATMENT OUTCOME;

EID: 3142742213     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0001-6349.2004.00433.x     Document Type: Article

References (52)

1. Ylikorkala O, Dawood MY. New concepts in dysmenorrhea. Am J Obstet Gynecol 1978; 130: 833-47.
2. Lumsden MA. Dysmenorrhoea. Prog Obstet Gynaecol 1979; 42: 276-92.
3. Andersch B, Milsom I. An epidemiologic study of young women with dysmenorrhea. Am J Obstet Gynecol 1982; 144: 655-60.
4. Filler W, Hall W. Dysmenorrhea and its therapy: a uterine contractility study. Am J Obstet Gynecol 1970; 106: 104-9.
5. Pickles VR. Prostaglandins in the human endometrium. Int J Fertil 1967; 12: 335-38.
6. Pickles VR, Hall W, Best F, Smith G. Prostaglandins in endometrium and menstrual fluid from normal and dysmenorrhoeic subjects. J Obstet Gynaecol 1965; 72: 185-92.
7. Chan WY, Hill JC. Determination of menstrual prostaglandin levels in non-dysmenorrheic and dysmenorrheic subjects. Prostaglandins 1978; 15: 365-75.
8. Lundström V, Green K. Endogenous levels of prostaglandin F2α and its main metabolites in plasma and endometrium of normal and dysmenorrheic women. Am Obstet Gynecol 1978; 130: 640-6.
9. Dawood Y. Current concepts in the aetiology and treatment of primary dysmenorrhea. Acta Obstet Gynecol Scand Suppl 1986; 138: 7-10.
10. Benassi L, Bertani D, Avanzini A. An attempt at real prophylaxis of primary dysmenorrhea: comparison between meclofenamate sodium and naproxen sodium. Clin Exp Obstet Gynecol 1993; 2: 102-7.
11. Delgado J, Simonin G, Servier C, García R, Yoma J. Tolfenamic acid and mefenamic acid in the treatment of primary dysmenorrhoea. Pharmacol Toxicol 1994; 75 (Suppl II): 89-91.
12. Pasquale S, Rathauser R, Dolese HM. A double-blind, placebo-controlled study comparing three single-dose regimens of piroxicam with ibuprofen in patients with primary dysmenorrhea. Am J Med 1988; 84 (Suppl 5): 30-4.
13. Lundström V, Gréen K, Wiqvist N, Prostaglandins, indomethacin and dysmenorrhea. Prostaglandins 1976; 11: 893-904.
14. Csapo AJ, Pulkkinen MO, Henzl MR. The effect of naproxensodium on the intrauterine pressure and menstrual pain of dysmenorrheic patients. Prostaglandins 1977; 13: 193-9.
15. Smith R, Powell R. Intrauterine pressure changes during dysmenorrhea therapy. Am J Obstet Gynecol 1982; 143: 286-9.
16. Hanft G. Meloxicam investigator's brochure, 11th edn. 1998.
17. Vane J. Towards a better aspirin. Nature 1994; 367: 215-16.
18. Battistini B, Bolting R, Bakhle YS. COX-1 and COX-2: toward the development of more selective NSAIDs. Drug News Perspect 1994; 7: 501-12.
19. Dequeker J, Degner F. Editorial (meloxicam). Inflamm Res 2001; 50 (Suppl 1): S3-S4.
20. Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 1996; 35 (Suppl 1): 68-77.
21. Smith TJ, Cyclooxygenases as the principal targets for the action of NSAIDs. Rheum Dis Clin North Am 1998; 24: 501-23.
22. DeWitt D. Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim Biophys Acta 1991; 1083: 121-34.
23. Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993; 11: 371-86.
24. Kömhoff M, Gröne H-J, Klein T, Seyberth HW, Nüsing RM. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol 1997; 272: F460-8.
25. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 15: 787-96.
26. Meade EA, Smith WL, deWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal anti-inflammatory drugs. J Biol Chem 1993; 268: 6610-14.
27. Bakhle YS, Botting RM. Cyclooxygenase-2 and its regulation in inflammation. Mediators Inflamm 1996; 305-23.
28. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and non-ulcerogenic. Proc Natl Acad Sci USA 1994; 91: 3228-32.
29. Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L745.337 - a novel nonsteroidal antiinflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 1995; 273: 1531-7.
30. Dawood MY. Nonsteroidal antiinflammatory drugs and reproduction. Am J Obstet Gynecol 1993; 169: 1255-65.
31. Bieglmayer C, Hofer G, Kainz C, Reinthaller A, Kopp B, Janisch H. Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. Gynecol Endocrinol 1995; 9: 307-12.
32. Nigam S, Benedetto C, Zonca M, Leo-Rossberg I, Lubbert H, Hammerstein J. Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea. Eicosanoids 1991; 4: 137-41.
33. Chan WY, Dawood MY, Fuchs F. Relief of dysmenorrhea with the prostaglandin synthetase inhibitor ibuprofen: effect on prostaglandin levels in menstrual fluid. Am J Obstet Gynecol 1979; 135: 1255-65.
34. Chan WY, Fuchs F, Powell M. Effects of naproxen sodium on menstrual prostaglandins and primary dysmenorrhea. Obstet Gynecol 1983; 61: 285-91.
35. Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R, Trzaskos JM et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997; 91: 197-208.
36. Engelhardt G. Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with a improved safety profile through preferential inhibition of COX-2. Br J Rheumatol 1996; 35: 4-12.
37. Mehlisch DR, Fulmer RI. A crossover comparison of bromfenac sodium, naproxen sodium, and placebo for relief of pain from primary dysmenorrhea. J Womens Health 1997; 6: 83-92.
38. Ehrich E, Schnitzer T, Kivitz A, Weaver A, Wolfe F, Morrison B. MK-966, a highly selective Cox-2 inhibitor, was effective in the treatment of osteoarthritis of the knee and hip in a 6-week placebo controlled study. Arthritis Rheum 1997; 40 (Suppl 9): S85.
39. Schroeder B, Sanfilippo JS. Dysmenorrhea and pelvic pain in adolescents. Pediatr Clin North Am 1999; 46: 555-68.
40. Hillen TIJ, Grbavac SL, Johnston PJ, Straton JAY, Keogh JMF. Primary dysmenorrhea in young Western Australian women: prevalence, impact and knowledge of treatment. J Adolesc Health 1999; 25: 40-5.
41. Casamitjana Cucurella N, Gascon Lecha P. Dysmenorrhea. Circ Farm 1998; 56: 10-12.
42. De Costa C. Menorrhagia and intermenstrual bleeding. Mod Med Aust 1998; 41: 76-85.
43. Zhang WY, Li Wan Po A. Efficacy of minor analgesics in primary dysmenorrhoea: a systematic review. Br J Obstet Gynaecol 1998; 105: 780-9.
44. Berry M. Dysmenorrhea. Can Pharm J 1998; 131: 7-16.
45. Muniz Ribeiro R, Rezende WW. Dysmenorrhea. Rev Bras Med 1997; 53: 143-4, 148.
46. Ticconi C, Pietropolli A, Piccione E. Dysmenorrhea. G Ital Ostet Ginecol 1997; 19: 581-91.
47. Venturini PL, Fasce V, Gorlero F, Ginocchio G. Chronic pelvic pain: oral contraceptives and non-steroidal antiinflammatory compounds. Cephalalgia 1997; 17: 29-31.
48. Da Fonseca AM, Bagnoli VR. Dysmenorrhea. Rev Bras Med 1997; 54: 44-51.
49. O'Connell BJ. The pediatrician and the sexually active adolescent: treatment of common menstrual disorders, Pediatr Clin North Am 1997; 44: 1391-404.
50. Cohen J. Statistical power analysis for the behavioral sciences. New York: Academic Press, 1969.
51. Chuang-Stein C. Summarising laboratory data with different reference ranges in multicentre clinical trials. Drug Inf J 1992; 26: 77-84.
52. Seibert K, Masferrer JL. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor 1994; 4: 17-23.